168626-94-6

Basic information

• Product Name: Conivaptan hydrochloride
• Synonyms: (1,1'-Biphenyl)-2-carboxamide, N-(4-((4,5-dihydro-2-methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)phenyl)-, monohydrochloride;Conivaptan HCl;Conivaptan hydrochloride [usan];Unii-75L57R6X36;Vaprisol;Conivaptan hydrochkoride;N-[4-[(4,5-Dihydro-2-MethyliMidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-[1,1'-Biphenyl]-2-carboxaMide Hydrochloride;Conivaptan HCI
• CAS NO: 168626-94-6
• Molecular Formula: C32H26N4O2.HCl
• Molecular Weight: 535.04
• EINECS: 1312995-182-4
• Product Categories: Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals;Inhibitors
• Mol File: 168626-94-6.mol

Chemical Properties

• Melting Point: >250°
• Boiling Point: 751.2 °C at 760 mmHg
• Flash Point: 408.1 °C
• Appearance: /
• Vapor Pressure: 1.89E-22mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: Conivaptan hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Conivaptan hydrochloride(168626-94-6)
• EPA Substance Registry System: Conivaptan hydrochloride(168626-94-6)

Safety Data

• Hazardous Substances Data: 168626-94-6(Hazardous Substances Data)

Usage

Uses

1. Used in the Treatment of Hyponatremia:
Conivaptan hydrochloride is used as a therapeutic agent for the treatment of hyponatremia, particularly in cases caused by SIADH. It helps to increase serum sodium concentration and reduce total body volume by blocking the renal V2 receptor, resulting in enhanced diuresis.
2. Used in the Treatment of Congestive Heart Failure:
Conivaptan hydrochloride is used as a vasopressin receptor antagonist in the treatment of congestive heart failure. It modulates systemic vascular resistance through the V1a receptor, which is distributed in vascular smooth muscle cells, cardiomyocytes, hepatocytes, and platelets. This action helps to restore volume homeostasis and alleviate the symptoms of congestive heart failure.
3. Used in the Management of Syndrome of Inappropriate Antidiuretic Hormone (SIADH):
Conivaptan hydrochloride is used as a treatment option for SIADH, a condition characterized by an imbalance of sodium and water in the body due to elevated levels of arginine vasopressin. By antagonizing vasopressin receptors, conivaptan hydrochloride helps to restore homeostasis and manage the symptoms associated with SIADH.
4. Used in the Treatment of Other Diseases:
Conivaptan hydrochloride has shown promise as a potential treatment option for other diseases, such as diabetes insipidus and liver cirrhosis. Its dual V1a and V2 vasopressin receptor antagonist properties make it a versatile candidate for further research and development in these areas.
5. Used in Experimental Stroke Models:
Conivaptan hydrochloride is used as a therapeutic agent in mouse experimental stroke models. It has been shown to reduce brain edema and blood-brain barrier disruption, which are critical factors in the progression of stroke and its associated complications.

Originator

Yamanouchi (Japan)

InChI:InChI=1/C32H26N4O2.ClH/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22;/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37);1H

Upstream product

• 29489-04-1 4-bromo-1-[(4-methylphenyl)sulfonyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-one 
• 50998-74-8 methyl N-tosylanthranilate 
• 122-04-3 4-nitro-benzoyl chloride 
• 134-20-3 2-carbomethoxyaniline 
• 14002-52-9 o-phenylbenzoyl chloride 
• 195531-22-7 {4-[(2-methyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl}amine 
• 168626-74-2 4-[([1,1'-Biphenyl]-2-carbonyl)amino]benzoic Acid 
• 318237-73-9 2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine 
• 124-42-5 acetamidine hydrochloride 
• 62-53-3 aniline 
• 62-23-7 4-nitro-benzoic acid 
• 3460-11-5 4-nitrobenzanilide 
• 24310-36-9 1-tosyl-2,3,4,5-tetrahydro-1H-1-benzazepin-5-one 
• 68595-19-7 1-[(4-methylphenyl)sulfonyl]-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine-4-carbonitrile 

Relevant articles and documents

Preparation method of conivaptan hydrochloride

The invention discloses a preparation method of conivaptan hydrochloride. The preparation method includes: taking aniline (compound I) as a raw material which is subjected to amidation, alkylation, friedel-crafts acylation, nitro reduction, amidation, alpha-chloro, cyclization and salt-forming reaction to obtain the conivaptan hydrochloride. With the method, the aniline is taken as the raw material easy to obtain, and toxic substances of acyl chloride and the like are avoided during amidation. The entire synthesis process is small in pollution and easy to process with the brand new synthesis theory, and reaction conditions of procedures are moderate; the preparation method is moderate in reaction condition of each procedure, simple in operation, high in yield and purity, environment friendly, low in production cost and suitable in industrial production.

A scalable process for the synthesis of 2-methyl-1,4,5,6- tetrahydroimidazo[4,5-d][1]benzazepine monohydrate and 4-[(biphenyl-2- ylcarbonyl)amino]benzoic acid: Two new key intermediates for the synthesis of the AVP antagonist conivaptan hydrochloride

A process for the multikilogram synthesis of the dual vasopressin-receptor antagonist, conivaptan hydrochloride, has been developed. This method relies on the introduction of operationally simple chemistry during the final stages of the process when two k

A new synthetic route to YM087, an arginine vasopressin antagonist

A new synthesis of N-{4-[(2-methyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl} biphenyl-2-carboxamide monohydrochloride (1, YM087) via new imidazobenzazepine intermediates is described. This method remarkably improves the overall yiel

Practical Synthesis of N-{4-[(2-Methyl-4,5-dihydroimidazo[4,5-d][1] benzazepin-6(1H)-yl)carbonyl]phenyl}biphenyl-2-carboxamide Monohydrochloride: An Arginine Vasopressin Antagonist

A novel, reliable, and cost-effective synthetic route to N-{4-[(2-methyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl] -phenyl}biphenyl-2-carboxamide monohydrochloride (1, YM087), a potent Arginine vasopressin antagonist, has been developed. Using moisture-controlled potassium carbonate, imidazole formation from α-bromoketone furnished imidazobenzazepine, avoiding potential oxazole-ring formation. Catalytic reduction of nitro imidazobenzazepine afforded the corresponding amine in high yields. Treatment of the imidazole-containing amine directly, with a carbonyl chloride, afforded the target amide circumventing protection of the imidazole.

Condensed benzazepine derivative and pharmaceutical composition thereof

This invention relates to nitrogen-containing aromatic 5-membered ring-condensed benzazepine derivatives represented by the general formula (I) STR1 (symbols in the formula have the following meanings; ring B: a nitrogen-containing aromatic 5-membered ring having at least 1 nitrogen atom and optionally one oxygen or sulfur atom, which may optionally have substituent(s), R1 and R2 : these may be the same or different from each other and each represents a hydrogen atom, a halogen atom, a lower alkyl group, an amino group which may optionally be substituted by lower alkyl group(s), or a lower alkoxy group, A: a single bond; a group represented by the formula n: 0 or an integer of from 1 to 3, R3 and R4 : these may be the same or different from each other and each represents a hydrogen atom, a lower alkyl group (provided that R3 and R4 may together form a lower alkylene group having 2 to 7 carbon atoms), and ring C: a benzene ring which may optionally have substituent(s)) and salts thereof; to pharmaceutical compositions which contain these compounds as an active ingredient and to intermediates which are useful in synthesizing these compounds. The compounds of this invention are useful as arginine vasopressin antagonists.